Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2510924 plus Sunitinib in Metastatic Renal Cell Carcinoma
NCT01391130Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2011
- Primary completion
- Sep 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LY2510924 in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression Free Survival up to 67 Months. Started Aug 2011; status: terminated.
02
Drugs
LY2510924
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT01391130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01391130.